AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

AbbVie stock cuts its Q3 EPS guidance to USD 3.730-3.770

Guidance lowered AI-generated analysis

πŸ“‰ AbbVie lowered its Q3 2026 adjusted EPS guidance to USD 3.730-3.770, missing the USD 3.850 consensus estimate.

πŸ’° The guidance reduction is driven by USD 216 million in acquired in-process R&D and milestone expenses.

πŸ“ˆ Q2 2026 revenue surged to USD 16.99 billion, representing a 10.2% year-over-year increase.

πŸš€ Q2 adjusted EPS hit USD 3.65, up from USD 2.97 in the same quarter last year.

🏦 Bank of America raised its price target to USD 289 and maintained a Buy rating on September 29.

🎯 The average analyst price target is USD 278.86, implying upside from the current trading price.

πŸ“… AbbVie will report Q3 results on October 30, 2026, before the market opens.

πŸ’Ή Stock traded at USD 265.96 on October 6, up 0.08% and near its 52-week high of USD 269.39.

🏒 Market capitalization stands at USD 469.9 billion as of October 6, 2026.

Bullish Signals
  • AbbVie reported strong Q2 2026 revenue growth of 10.2% year-over-year, reaching USD 16.99 billion.
  • The company delivered adjusted EPS of USD 3.65 in Q2, a significant increase from USD 2.97 the prior year.
  • Bank of America raised its price target to USD 289 and maintained a Buy rating on September 29.
  • Analyst consensus remains bullish with an average price target of USD 278.86, trading above current levels.
Risk Factors
  • AbbVie cut its Q3 2026 adjusted EPS guidance to USD 3.730-3.770, below the USD 3.850 consensus.
  • The lower guidance range reflects a one-time impact of USD 216 million in acquired in-process R&D and milestone expenses.
Full Analysis
AbbVie Inc. has lowered its third-quarter 2026 adjusted earnings per share (EPS) guidance to a range of USD 3.730-3.770, which falls below the market consensus estimate of USD 3.850. The company attributes this downward revision primarily to acquired in-process research and development costs and milestone expenses totaling USD 216 million. Despite the guidance cut, AbbVie reported robust financial performance for the second quarter of 2026, generating revenue of USD 16.99 billion, a 10.2% year-over-year increase. Adjusted EPS for Q2 reached USD 3.65, significantly beating the prior-year figure of USD 2.97, indicating strong underlying operating growth. Analyst sentiment remains cautiously optimistic despite the guidance adjustment. Major institutions like Bank of America have maintained Buy ratings and raised price targets, with an average analyst target currently standing at USD 278.86. The stock is trading near its 52-week high, suggesting investors are weighing the near-term expense headwinds against long-term growth potential. AbbVie is scheduled to release its official third-quarter results on October 30, 2026, before the market opens. Market attention will focus on whether the company's revenue growth trajectory can successfully offset the impact of the lower EPS guidance and the specific expense items included in the revision.